Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Reishi D. International, Inc.
WARNING LETTER
•Reishi D. International, Inc.•August 7, 2017

Reishi D. International, Inc. – FDA Warning Letter, Aug 7, 2017

Record Details

On August 2-7, 2017, the FDA inspected Reishi D. International, Inc.'s dietary supplement facility. The inspection revealed serious violations of cGMP regulations (21 CFR Part 111), causing the Reishi D. product to be adulterated under 21 U.S.C. § 342(g)(1). Additionally, product labels and brochures contained violations of the Federal Food, Drug, and Cosmetic Act.

The FDA determined that claims on product brochures, such as "Chinese medicine" and "Propolis...help to neutralize the free radicals and prevent cell damage," establish Reishi D. as an unapproved new drug under 21 U.S.C. § 321(g)(1)(B) and § 321(p)(1), as it is intended for disease treatment or prevention and is not generally recognized as safe and effective. Introducing such a product into interstate commerce without FDA approval violates 21 U.S.C. § 331(d) and § 355(a).

Even if not an unapproved drug, the product is adulterated due to cGMP violations. The firm, as a distributor, is ultimately responsible for ensuring compliance. Significant violations include: 1. Failure of the quality control unit to approve or reject packaged and labeled dietary supplements for distribution, as required by 21 CFR 11

Company
Reishi D. International, Inc.
Inspection date
August 7, 2017
Product type
Food
Office
San Francisco District Office
People
  • Darla R. Bracy
  • Matthew A. Walburger (Compliance Officer)
  • Tammy Hancock
  • Shuo Lin Xu
View Company Profile

ID · 8be848fc-582b-4d4c-a20c-d5e3a8085364

Violation Codes10
21 CFR 11121 U.S.C. 342(g)(1)21 U.S.C. 321(g)(1)(B)21 U.S.C. 321(p)(1)21 U.S.C. 331(d)21.U.S.C. 355(a)21 U.S.C. 343(s)(2)(C)21 U.S.C. 343(q)(1)(A)21 U.S.C. 379j-3121 CFR 111.127(h)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Reishi D. International, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.